Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Fiche publication
Date publication
février 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc
Tous les auteurs :
Acres B, Lacoste G, Limacher JM
Lien Pubmed
Résumé
Several approaches to antigen-specific immunotherapy of cancer antigen-specific immunotherapy of cancerantigen-specific immunotherapy of cancer have been tested clinically. In this chapter, we will describe studies done with the antigen MUC1. Tested MUC1 therapeutic vaccinesMUC1 therapeutic vaccines include the following: monoclonal antibodies (MAbs) specific for MUC1; synthetic and recombinant polypeptides from the protein sequence of MUC1; dendritic cells carrying MUC1; RNA and DNA vaccinations; and recombinant viruses carrying the MUC1 DNA sequence. Chemotherapy of cancer aims to be toxic to the cancer cells with manageable side effects to the patient. In contrast, antigen-specific immunotherapy of cancer aims to treat the patient, such that the patient is then able to control and eventually eliminate their cancer cells. It is therefore important to know the immune statusimmune status of each cancer patientcancer patient prior to therapy.
Référence
Curr Top Microbiol Immunol. 2015 Feb 22.